Article Text

Download PDFPDF

#63 Central nervous system metastasis in gynecologic cancers: seeking the prognostic factors
  1. Yagmur Minareci1,
  2. Naziye Ak2,
  3. Ozgur Aydin Tosun3,
  4. Hamdullah Sozen4,
  5. Samet Topuz1 and
  6. Yavuz Mehmet Salihoglu1
  1. 1Istanbul University, Faculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul, Turkey
  2. 2Istanbul University, Institute of Oncology, Department of Medical Oncology, Istanbul, Turkey
  3. 3Istanbul Medeniyet University, Goztepe Research and Training Hospital, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul, Turkey
  4. 4Istanbul University, Faculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul, Türkiye


Introduction/Background Central nervous system (CNS) metastasis originating from gynecological cancer is a rare and late manifestation of the disease. Therefore, there is still limited data on prognostic factors for survival. The objective of the present study is to identify prognostic factors for survival in patients with CNS metastasis originating from gynecological cancer.

Methodology The present retrospective study analyzed the patients with gynecological cancers who were treated due to CNS metastases between January 1999 and December 2019 at Istanbul University Hospital. Gynecological cancers were divided into four groups according to their origin, including epithelial ovarian cancer, endometrial cancer, cervical cancer, and vulvar cancer. Treatment-free interval(TFI) was determined as the time from the last treatment of gynecologic cancer to the diagnosis of CNS metastasis.

Results Forty-seven patients with CNS metastasis of gynecological origin were included in the study. The median age at the time of CNS metastasis was 59 (range 34 – 93). Median time from initial cancer diagnosis to CNS metastasis was 24.9 (range: 0 – 108.2) months. Most patients had epithelial ovarian cancer (76.6%), followed by endometrial cancer (14.8%), cervical cancer (4.3%), and vulvar cancer (4.3%). By multivariate analysis, the presence of extracranial metastasis (HR: 5.10; 95% CI:1.71–15.18), Eastern Cooperative Oncology Group (ECOG) performance status ≥3 (HR: 2.92; 95% CI: 1.36–6.26), palliative care only for the treatment of CNS metastasis (HR: 1.47; 95% CI:0.58–4.11) and treatment-free interval (TFI) <6 months (HR: 2.74; 95% CI:1.23–6.08) were independent factors that associated with worse survival.

Conclusion Patients with CNS metastasis who have favorable prognostic factors are considered to be appropriate candidates for aggressive and long-term treatment strategy. Extracranial metastasis, ECOG performance status, treatment history of CNS metastasis, and TFI were determined as independent prognostic factors that improved survival. TFI might be taken into account as a prognostic factor for patients with CNS metastasis in gynecological cancer.

Abstract #63 Figure 1

On the left: Kaplan-Meier survival curves after the diagnosis of CNS metastasis in all patients. mOS= median Overall Survival. Onthe Right: Kaplan-Meier survival curves of the patients by primary origin of the disease after the diagnosis of CNS metastasis. mOS= median Overall Survival.

Disclosures We declared that we have no conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.